Newsfeeds Archive - Page 24 of 56

2 minute read

Filament Health’s Q1 2023 Financial Results, Material Uncertainty On The Horizon

May 15, 2:15 PM

Natural psychedelics drug developer Filament Health Corp. (OTCQB: FLHLF) shared its interim financial results and further business highlights for the first quarter ended March 31, 2023.

FLHLF

4 minute read

EXCLUSIVE: Lessons From Psychedelics Markets Through Business, Legal And Reciprocity Lenses

By Lara Goldstein

May 12, 7:37 PM

This year’s edition of Benzinga’s Psychedelics Capital Conference hosted some of the most knowledgeable panelists and hot-button discussions currently in the space.

BWVI

2 minute read

EXCLUSIVE: Clearmind Medicine Secures Approval To Launch Clinical Trial For Alcohol Addiction Treatment

By Lara Goldstein

May 12, 8:30 AM

Clearmind Medicine Inc.

CMND

1 minute read

New Psilocybin Chocolate Bar By Vertical Cannabis And Psychedelics Company

By Lara Goldstein

May 11, 4:04 PM

Holistic wellness company Kaya Group’s (OTC: NUGL) subsidiary Kaya Extracts is expanding its product offerings with two new psychedelic mushroom chocolates, available in Jamaica's legal psilocybin market.

NUGL

2 minute read

GH Research: Q1 2023 Financials And Businesses For European 5-MeO-DMT Depression Treatment Developer

By Lara Goldstein

May 11, 3:36 PM

GH Research PLC (NASDAQ: GHRS), a Dublin-based clinical-stage biotech company reported financial results for the first quarter ended March 31, 2023.

GHRS

2 minute read

COMPASS Pathways Reports Q1 2023: Financials, Commercial Groundwork And Ongoing Phase 3 Trials

By Lara Goldstein

May 11, 3:18 PM

Mental healthcare biotech company advancing psilocybin therapy COMPASS Pathways plc (NASDAQ: CMPS) reported its financial results for the first quarter 2023 ended March 31, 2023 and updated on recent business and clinical progresses. In numbers:

CMPS

1 minute read

Optimi Health Boosts Psilocybin Production With New Health Canada License And Supply Deal

By Lara Goldstein

May 11, 2:42 PM

Psychedelics research and manufacturing company Optimi Health Corp. (OTCQX: OPTHF) received a “Natural Health Product Site" license, adding to its existing permits to produce and supply psychedelic substances including MDMA and psilocybin.

OPTHF

2 minute read

Atai Life Sciences Q1 2023 Results, Pipeline Update On DMT And Psilocybin Clinical Trials

By Lara Goldstein

May 11, 2:11 PM

Clinical-stage biopharma company atai Life Sciences (NASDAQ: ATAI) reported the financial results for its first quarter ended March 31, 2023, and provided the period’s business highlights. Consolidated quarterly financials:

ATAI

1 minute read

Promising Multiple Sclerosis Drug Candidate Advances: First Clinical Trial Dosing Completed

By Lara Goldstein

May 10, 4:23 PM

FSD Pharma Inc. (NASDAQ: HUGE), a biopharma company developing innovative assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, announced the first cohort of participants on its

HUGE

1 minute read

Stress-Related Mood Disorders And Alzheimer’s: Can This Patented Ketamine Drug Help?

By Lara Goldstein

May 10, 11:15 AM

Silo Pharma Inc. (NASDAQ: SILO), one of the biotech companies developing next-generation psychedelic therapeutics, obtained a new US patent covering IP for its drug candidate SPC-15’s research and development.

SILO